Item 5.07. Submission of Matters to a Vote of Security Holders.

On December 16, 2021, CM Life Sciences III Inc., a Delaware corporation ("CMLS III"), held a Special Meeting of its stockholders (the "Special Meeting"). At the Special Meeting, a total of 53,077,371 (approximately 76.92%) of CMLS III's issued and outstanding shares of common stock held of record as of November 4, 2021, the record date for the Special Meeting, were present either in person or represented by proxy, which constituted a quorum. CMLS III's stockholders voted on the following proposals at the Special Meeting, each of which was approved. The final vote tabulation for each proposal is set forth below.

(a) Proposal No. 1 - The Business Combination Proposal - to approve and adopt the


     Agreement and Plan of Merger, dated as of August 5, 2021, as amended by
     Amendment No. 1 and Amendment No. 2 thereto (the "amendments"), dated as of
     September 21, 2021 and October 28, 2021, respectively (as so amended and as
     may be further amended and/or restated from time to time, the "Merger
     Agreement"), by and among CMLS III, its wholly owned subsidiary, Clover III
     Merger Sub, Inc. ("Merger Sub"), and EQRx, Inc. ("EQRx"), a composite copy of
     which, incorporating the amendments into the text of the initial agreement,
     is attached to the Definitive Proxy Statement, as filed December 1, 2021,
     as Annex A, and approve the transactions contemplated thereby ("Business
     Combination"), including the merger of Merger Sub with and into EQRx, with
     EQRx surviving the merger as a wholly owned subsidiary of CMLS III, and the
     issuance of common stock to EQRx stockholders as merger consideration:




Class A Shares   Votes For  Votes Against Abstentions
                 36,260,098   3,017,927      2,345

Class B Shares   Votes For  Votes Against Abstentions
                 13,800,000       0            0

(b) Proposal No. 2 - The Nasdaq Stock Issuance Proposal - to approve, assuming


     the Business Combination Proposal is approved, and for purposes of complying
     with applicable listing rules of the Nasdaq Stock Market ("Nasdaq"), the
     issuance of more than 20% of CMLS III's outstanding common stock in
     connection with the Business Combination and subscription agreements dated as
     of August 5, 2021 with certain institutional investors (collectively, the
     "PIPE Investors"), including up to 120,000,000 shares of our common stock to
     the PIPE Investors, which includes affiliates of CMLS Holdings III LLC
     ("Sponsor") that subscribed for 10,250,000 shares of common stock, and up to
     365,000,000 shares of our common stock to EQRx stockholders and up to
     50,000,000 Earn-Out Shares:

Class A Shares Votes For Votes Against Abstentions


                 36,256,997   3,017,340      6,033

Class B Shares Votes For Votes Against Abstentions


                 13,800,000       0            0

(c) Proposal No. 3 - The Incentive Plan Proposal - to approve the EQRx, Inc. 2021


     Stock Option and Incentive Plan, a copy of which is attached to the
     Definitive Proxy Statement filed December 1, 2021, as Annex C ("2021
     Incentive Plan"), including the authorization of the initial share reserve
     under the Incentive Plan:




Class A Shares   Votes For  Votes Against Abstentions
                 32,605,631   6,649,638     25,101

Class B Shares   Votes For  Votes Against Abstentions
                 13,800,000       0            0

(d) Proposal No.4 - The ESPP Proposal - to approve the EQRx, Inc. 2021 Employee


     Stock Purchase Plan, a copy of which is attached to the Definitive Proxy
     Statement filed December 1, 2021 as Annex D ("ESPP"), including the
     authorization of the initial share reserve under the ESPP:




Class A Shares   Votes For  Votes Against Abstentions
                 32,952,962   6,304,628     22,780

Class B Shares   Votes For  Votes Against Abstentions
                 13,800,000       0            0

(e) Proposal No. 5 - The Charter Amendment Proposal - to, assuming the Business


     Combination Proposal is approved, adopt the A&R Certificate of Incorporation
     in the form attached to the Definitive Proxy Statement filed December 1, 2021
     as Annex E:




Class A Shares   Votes For  Votes Against Abstentions
                 36,248,569   3,024,996      6,805

Class B Shares   Votes For  Votes Against Abstentions
                 13,800,000       0            0

© Edgar Online, source Glimpses